Lifeist Wellness Inc said its newly launched biosciences and consumer wellness subsidiary, Mikra Cellular Sciences Inc is poised to launch its first product, CELLF, a novel cellular therapeutic compound targeting systemic fatigue.
As part of the pre-launch activities of CELLF, Lifeist said Mikra has filed a patent application with the United States Patent and Trademark Office and partnered with InVivo Biosystems Inc for pre-clinical trials to strengthen its patent claim.
In a statement, Faraaz Jamal, COO of Lifeist and CEO of Mikra commented: “The real health crisis isn’t reduced longevity — we’re living longer than we have in the past. It’s extended morbidity that’s the problem. While we’re all familiar with mortality, morbidity is attributable to age-related diseases that lower your quality of life which is why so many of us when we hit our 30’s, 40’s and 50’s experience multiple physiological and mental walls — notably brain fog, fatigue, and inflammation. This all happens at a cellular level, and it can cascade into poor sleep, mood drops, and an inability to enjoy life like you want to."
“With that in mind, I’m extremely excited to present Mikra’s first product, CELLF (pronounced “self”). We engineered this product for everyone who has started to feel like their biological age is affecting their everyday performance and ability to feel like the best version of themselves," he added.
Jamal continued: “CELLF works at a cellular level to help combat systemic fatigue, inflammation, and brain fog by promoting the creation of mitochondria and subsequently increasing their efficiency. This is in addition to the upregulation and downregulation of certain cellular detoxification pathways that can remove the buildup of senescent (old/dysfunctional) cells that may cause excessive chronic inflammation and uncontrolled cell division.”
CELLF is manufactured in a proprietary oxygen-deprived environment to maintain biopotency and bioavailability with clinically tested United States Food & Drug Administration (FDA) certified GRAS (generally recognized as safe) bioactive ingredients.
The CELLF compound delivery system is a two-stage, patented mechanism — it is first bound to a transferrin glycoprotein and then encapsulated within a liposome. This allows safe passage of CELLF through the gastric environment and delivery directly into the blood plasma. The result is optimal delivery of our compound with minimal degradation to the best site of absorption. CELLF will be shipped in a package containing 30 X 10ml single-serve sachets to prevent oxidation and maximize bioavailability.
“You’ve got to satisfy two conditions for a product like this to work. The first is that the molecules within the compound need to be backed by rigorous science. The second is that you need to deliver it effectively into your body, and more specifically, your cells so that it is maximally absorbed. Very few products satisfy the first, let alone the second,” said Jamal. “As one of my lifelong heroes, Carl Sagan once said, ‘extraordinary claims require extraordinary evidence’, which is why we’ve partnered with Invivo Biosystems to prove and strengthen our patent claim that CELLF does both.”
Mikra Partners with InVivo Biosystems
Lifeist also said Mikra has partnered with InVivo Biosystems, experts in genetic model creation and in vivo testing, to strengthen its patent application by conducting a pre-clinical study identifying genetic signatures and pathways associated with average human healthspans and to test the effects of CELLF on healthy aging.
“We are proud to partner with Mikra in developing a family of healthy living products that reduce biological aging. At InVivo Biosystems, we take a systematic, multi-omics approach to make gene-by-gene discoveries and uncover the different genetic pathways that are up or down regulated during aging. The InVivo Longevity Platform measures the complex interplay of cellular proliferation, autophagy, mitochondrial oxidative stress, genetic predisposition, and transcriptional changes that occur during aging,” said Dr Chris Hopkins, chief science officer at InVivo Biosystems.
“In our collaboration with Mikra, we are exploring how its flagship formulation, CELLF, increases the efficiency of mitochondrial ATP production and cellular respiration. Using the InVivo Longevity Platform, we measure at the molecular level how Mikra’s CELLF formulation can counter periodic bouts of fatigue by providing improved cellular respiration. In our partnership, we will be generating the science-based evidence that Mikra can use as further backbone for their intellectual property claims. Here at InVivo Biosystems we are also excited to continue partnering with Mikra in the future to uncover further how CELLF, and their future product lines, can create a new baseline for healthy living after 30," he added.
InVivo Biosystems is an expert in genetics, delivers scientific proof and evidence for ingredients at the molecular and cellular level via a proprietary analytical approach. Its analytical platform helps branded ingredient developers and manufacturers substantiate their product claims, file IP patents, or refine their formulations using the best science-backed measure of outcome.
“I’m very excited about adding incremental value to Lifeist shareholders and unlocking the earnings potential of Mikra and subsequently Lifeist. We’re taking the first steps here with bringing something novel to the market, validating and protecting it. But let’s be clear, it’s only the first step,” said Meni Morim, CEO of Lifeist.
“The initial traction Mikra has had around the pre-launch has been very promising — to grow to a community of nearly 20,000 with a huge level of engagement, in such a short amount of time and with no sign of stopping is a testament to the team’s expertise and validates the consumer’s desire for this type of product," Morim added.
Mikra’s CELLF will be available for pre-sale in mid-Q1 2022 with a waitlist sign up available at www.wearemikra.com. CELLF will be available on www.wearemikra.com and Amazon following the pre-sale for full public launch.
Lifeist is a portfolio of wellness companies leveraging advancements in science and technology to enable individuals to find their personalized path to wellness.
The company's portfolio business units include CannMart, which operates a B2B wholesale distribution business facilitating recreational sales to Canadian provincial government control boards and the CannMart.com marketplace which provides Canadian medical customers with a diverse selection of cannabis products from a multitude of federally licensed cultivators and its US customers with access to hemp-derived CBD and smoking accessories.
It also owns Australian Vapes, the country’s largest online retailer of vaporizers and accessories; Findify, a leading AI-powered search and discovery platform; and Mikra, a biosciences and consumer wellness company seeking to develop innovative therapies for cellular health and recovery.
Contact the author at jon.hopkins@proactiveinvestors.com